Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$205.00K$205.00Kderived−66.8% vs Q4 2013 Net Income-$1.14M-$1.14MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,150,000N/M Operating Cash Flowderived-$684,000N/M Free Cash Flowderived-$684,000N/M Margins · derivedOperating margin-561.0%−350.0 pt vs Q4 2013
Net margin-556.6%−343.0 pt vs Q4 2013
ended Jun 30, 2014 · filed Sep 29, 2014 · 91 d after period end